PAREXEL International Co. (PRXL) issued an update on its FY13 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $1.48-1.56 for the period, compared to the Thomson Reuters consensus estimate of $1.41. The company issued revenue guidance of $1.695-1.710 billion, compared to the consensus revenue estimate of $1.69 billion.PAREXEL International also updated its Q3 guidance to $0.38-0.42 EPS. PAREXEL International Co. (PRXL) traded down 0.29% on Tuesday, hitting $33.86. PAREXEL International Co. (PRXL) has a 1-year low of $22.47 and a 1-year high of $34.79. The stock?s 50-day moving average is currently $31.99. The company has a market cap of $1.992 billion and a price-to-earnings ratio of 29.82. PAREXEL International last issued its quarterly earnings data on Tuesday, January 29th. The company reported $0.41 earnings per share for the quarter, beating the analysts? consensus estimate of $0.33 by $0.08. The company had revenue of $422.10 million for the quarter, compared to the consensus estimate of $419.78 million. During the same quarter last year, the company posted $0.23 earnings per share. PAREXEL International?s revenue was up 26.7% compared to the same quarter last year. PAREXEL International has set its Q3 guidance at $0.38-0.42 EPS and its FY13 guidance at $1.48-1.56 EPS. Analysts expect that PAREXEL International Co. (PRXL) will post $1.41 EPS for the current fiscal year.
A number of analysts have recently weighed in on PRXL shares. Analysts at Robert W. Baird reiterated an outperform rating on shares of PAREXEL International in a research note to investors on Wednesday, January 16th. They now have a $34.00 price target on the stock, down previously from $37.00. On a related note, analysts at Sterne Agee reiterated an underperform rating on shares of PAREXEL International in a research note to investors on Monday, January 14th. They now have a $27.00 price target on the stock, up previously from $23.50. Finally, analysts at Goldman Sachs upgraded shares of PAREXEL International from a sell rating to a neutral rating in a research note to investors on Monday, January 14th. They now have a $36.00 price target on the stock, up previously from $28.00. PAREXEL International Corporation (PAREXEL) is a biopharmaceutical services company, providing a range of expertise in clinical research, medical communications, consulting, and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries.